iBio Inc

IBIO

Company Profile

  • Business description

    iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

  • Contact

    11750 Sorrento Valley Road
    Suite 200
    San DiegoCA92121
    USA

    T: +1 979 446-0027

    E: [email protected]

    https://www.ibioinc.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2027

    Employees

    23

iBio Inc News & Analysis

stocks

Looking under the hood at Robinhood

We review some of the platform's most popular stocks on 11 different measures of equity-related risk.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,836.6095.80-1.07%
CAC 408,146.8369.95-0.85%
DAX 4025,736.24309.13-1.19%
Dow JONES (US)50,198.17561.25-1.11%
FTSE 10010,551.17138.70-1.30%
HKSE22,827.98466.77-2.00%
NASDAQ24,429.88101.500.42%
Nikkei 22559,373.03348.750.59%
NZX 50 Index14,247.2517.04-0.12%
S&P 5007,323.6316.90-0.23%
S&P/ASX 2008,730.4091.40-1.04%
SSE Composite Index3,571.0016.83-0.47%

Market Movers